

## New nucleic acid expressed at high level in normal prostatic tissue and encoded polypeptides, used to treat cancer and screen for therapeutic agents

Publication number: JP2002505878T

Publication date: 2002-02-26

Inventor:

Applicant:

Classification:

- international: **A61P35/00; C07K14/47; C12N1/21; C12N15/12; A61K38/00; A61K48/00; A61P35/00; C07K14/435; C12N1/21; C12N15/12; A61K38/00; A61K48/00; (IPC1-7): C12N15/09; A61K38/00; A61K39/395; A61K48/00; A61P13/08; A61P35/00; C07K14/47; C07K16/18; C12N1/19; C12N1/21; C12N5/10; C12N15/02; C12P21/02; C12P21/08; G01N33/53**

- european: C07K14/47

Application number: JP20000535742T 19990309

Priority number(s): DE19981011194 19980310; WO1999DE00722 19990309

Also published as:



WO9946375 (A3)  
WO9946375 (A2)  
EP1068318 (A3)  
EP1068318 (A2)  
EP1068318 (A0)  
DE19811194 (A1)

less <<

Report a data error here

Abstract not available for JP2002505878T

Abstract of corresponding document: **DE19811194**

Nucleic acid sequences (A) that are expressed at high level in normal prostatic tissue and encode gene products or their fragments, are new. (A) is: (a) one of 64 sequences (all reproduced); (b) allelic variants of 40 of these sequences; or (c) the complements of these 40 sequences. Independent claims are also included for the following: (1) bacterial or phage artificial chromosomes, or cosmid clones, containing functional genes and their chromosomal locations corresponding to (A), for use as gene transfer vehicles; (2) fragments of (A) large enough to hybridize to (A); (3) expression cassette (EC) comprising (A), or its fragments, plus at least one control or regulatory element; (4) DNA fragments containing a gene obtained using (A); (5) host cells containing (A) or its fragments as a heterologous component of the genome; (6) recombinant production of polypeptides (I), or their fragments, by culturing these cells; (7) antibodies (Ab) directed against (I) or its fragments; (8) about 120 polypeptide partial sequences (I), all reproduced, and sequences at least 80 (especially 90) % homologous with them; (9) pharmaceutical composition containing at least one (I); and (10) genomic genes, or their promoters, enhancers, silencers, exon or intron structures, or slice variants, obtained using (A).

Data supplied from the esp@cenet database - Worldwide